AGP Executive Report
Last update: 10 hours agoIceland-Linked Eye Research: Iceland-listed Oculis reported progress on late-stage eye-drug trials, with results from its dry-eye study expected around year-end and a global optic-neuritis trial advancing. Cancer Vaccine Hopes: A South Iceland oncologist says a personalized mRNA vaccine showed promise in reducing melanoma recurrence after surgery; the approach remains under study and is not yet routine care. New Bladder Cancer Treatment: Anktiva, approved for use in Iceland and across Europe, has been given to its first European patients in Germany and Austria for hard-to-treat bladder cancer.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.